MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

ErbB-2 amplification/overexpression accounts for an aggressive breast cancer (BC) subtype (ErbB-2-positive). Enhanced ErbB-2 expression was also found in gastric cancer (GC) and has been correlated with poor clinical outcome. The ErbB-2-targeted therapies trastuzumab (TZ), a monoclonal antibody, and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Venturutti, L, Russo, RI Cordo, Rivas, MA, Mercogliano, MF, Izzo, F, Oakley, RH, Pereyra, MG, De Martino, M, Proietti, CJ, Yankilevich, P, Roa, JC, Guzmán, P, Cortese, E, Allemand, DH, Huang, TH, Charreau, EH, Cidlowski, JA, Schillaci, R, Elizalde, PV
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5832962/
https://ncbi.nlm.nih.gov/pubmed/27157613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.151
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados